DDInter1055 DDInter51
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
Levofloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Alogliptin
Levofloxacin {u} (Compound) causes {v} (Side Effect) Pancreatitis
Pancreatitis {u} (Side Effect) is caused by {v} (Compound) Alogliptin
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alogliptin
Levofloxacin {u} (Compound) resembles {v} (Compound) Gemifloxacin
Gemifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alogliptin
Levofloxacin {u} (Compound) resembles {v} (Compound) Gatifloxacin
Gatifloxacin {u} may lead to a major life threatening interaction when taken with {v} Alogliptin
Levofloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Linagliptin
Linagliptin {u} (Compound) resembles {v} (Compound) Alogliptin
Levofloxacin {u} (Compound) causes {v} (Side Effect) Pancreatitis
Pancreatitis {u} (Side Effect) is caused by {v} (Compound) Linagliptin
Linagliptin {u} (Compound) resembles {v} (Compound) Alogliptin
Levofloxacin {u} (Compound) causes {v} (Side Effect) Stevens-Johnson syndrome
Stevens-Johnson syndrome {u} (Side Effect) is caused by {v} (Compound) Hydrochlorothiazide
Hydrochlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alogliptin
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linagliptin
Linagliptin {u} (Compound) resembles {v} (Compound) Alogliptin
Levofloxacin {u} (Compound) resembles {v} (Compound) Gemifloxacin
Gemifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linagliptin
Linagliptin {u} (Compound) resembles {v} (Compound) Alogliptin
Levofloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alogliptin (Compound)
Levofloxacin (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Alogliptin (Compound)
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Levofloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Levofloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may lead to a major life threatening interaction when taken with Alogliptin
Levofloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound) and Linagliptin (Compound) resembles Alogliptin (Compound)
Levofloxacin (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Linagliptin (Compound) and Linagliptin (Compound) resembles Alogliptin (Compound)
Levofloxacin (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is caused by Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Levofloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)